Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05535218 |
| Title | Pembrolizumab-Sacituzumab Govitecan Combination to Treat High-risk, Localized Bladder Cancer (SURE-02) |
| Acronym | SURE-02 |
| Recruitment | Enrolling by invitation |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Claudia Guerrieri |
| Indications | |
| Therapies | |
| Age Groups: | senior | child | adult |
| Covered Countries | ITA |